Molecular Templates, Inc. is a clinical stage biopharmaceutical company that develops biologic therapeutics for cancer and other serious diseases through its proprietary biologic engineered toxin body (ETB) drug platform. Its pipeline of therapies includes MT-5111, MT-0169, and MT-6402 in Phase I clinical trials. The company also collaborates with Bristol Myers Squibb to discover and develop novel products containing ETBs.